Literature DB >> 2223592

Predicting response to chemotherapy for patients with epithelial ovarian cancer using urinary polyamine excretion patterns.

F G Lawton1, M Griffin, J A Slack, G Blackledge.   

Abstract

Urinary polyamine (UPA) excretion patterns were measured in 39 patients with clinically evaluable epithelial ovarian cancer immediately before they were treated with a cycle of chemotherapy and 24-48 h after chemotherapy to ascertain if changes in UPA excretion patterns correlated with eventual response to treatment. Almost all of the 19 patients who responded to chemotherapy had a rise in the excretion of all UPA fractions after treatment while most patients with chemoresistant cancer showed only an increase in the excretion of the putrescine and spermine fractions. However, a two-fold increase in excretion of the spermidine fractions occurred exclusively in patients who would eventually respond to chemotherapy. This phenomenon was not seen in patients with chemoresistant cancer. If, 48 h after chemotherapy, a patient with epithelial ovarian cancer does not show at least a doubling of the urinary levels of spermidine, acetylspermidine or total polyamine excretion that chemotherapy should be stopped since it is unlikely to be effective.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223592      PMCID: PMC1971469          DOI: 10.1038/bjc.1990.359

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer.

Authors:  F G Lawton; C W Redman; D M Luesley; K K Chan; G Blackledge
Journal:  Obstet Gynecol       Date:  1989-01       Impact factor: 7.661

Review 2.  Common epithelial cancer of the ovary (2).

Authors:  G S Richardson; R E Scully; N Nikrui; J H Nelson
Journal:  N Engl J Med       Date:  1985-02-21       Impact factor: 91.245

Review 3.  The human tumor colony-forming chemosensitivity assay: a biological and clinical review.

Authors:  E C Bradley; B F Issell; R Hellman
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Relationship of urinary polyamines to tumor activity and tumor volume in patients.

Authors:  Y Horn; S L Beal; N Walach; W P Lubich; L Spigel; L J Marton
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

5.  Elevation of monoacetylated polyamines in human breast cancers.

Authors:  A N Kingsnorth; H M Wallace
Journal:  Eur J Cancer Clin Oncol       Date:  1985-09

6.  Polyamines as markers of response and disease activity in cancer chemotherapy.

Authors:  B G Durie; S E Salmon; D H Russell
Journal:  Cancer Res       Date:  1977-01       Impact factor: 12.701

7.  Urinary polyamine excretion patterns in patients with epithelial ovarian cancer.

Authors:  F Lawton; M Griffin; J Slack; G Blackledge
Journal:  Gynecol Obstet Invest       Date:  1989       Impact factor: 2.031

8.  Urinary polyamines for evaluating the course of disease for patients with small cell carcinoma of the lung.

Authors:  K B Woo; T P Waalkes; M D Abeloff; R E Lenhard; C W Gehrke; K C Kuo
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

9.  Polyamines as predictors of success and failure in cancer chemotherapy.

Authors:  D H Russell; B G Durie; S E Salmon
Journal:  Lancet       Date:  1975-10-25       Impact factor: 79.321

  9 in total
  1 in total

1.  Detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via ATR-FTIR spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort.

Authors:  Panagiotis Giamougiannis; Camilo L M Morais; Brice Rodriguez; Nicholas J Wood; Pierre L Martin-Hirsch; Francis L Martin
Journal:  Anal Bioanal Chem       Date:  2021-07-01       Impact factor: 4.142

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.